Imviva Biotech Presents Studies on CTD402 Allogeneic CAR-T Therapy at EHA2026 Congress

▤ Summary

Imviva Biotech shared new clinical data on CTD402, its allogeneic anti-CD7 CAR-T therapy, at the EHA2026 Congress. The company reported encouraging response and remission rates in both adult and pediatric patients with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoblastic lymphoma. The data also showed a manageable safety profile with no reported neurotoxicity or graft-versus-host disease. Imviva highlighted CTD402’s off-the-shelf design and manufacturing consistency as key advantages for rapid treatment delivery. The trial is still enrolling, and the therapy remains investigational.

▦ Linked Companies